Company Overview of Adamas Pharmaceuticals, Inc.
Adamas Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems in the United States. The company’s lead product candidate ADS-5102, which completed the Phase II/III clinical trial for the treatment of Parkinson's disease, known as levodopa induced dyskinesia. Its product portfolio also includes memantine-based therapeutics, which include Namenda XR, a treatment of moderate to severe dementia associated with Alzheimer's disease; and Namzaric, a once-daily fixed-dose combination of Namenda XR, which is being co-developed with Forest Laboratories, Inc. The company was f...
1900 Powell Street
Emeryville, CA 94608
Founded in 2000
Key Executives for Adamas Pharmaceuticals, Inc.
Chairman and Chief Executive Officer
Total Annual Compensation: $748.8K
Chief Operating Officer
Total Annual Compensation: $436.1K
Senior Vice President of Product Development
Total Annual Compensation: $503.0K
Compensation as of Fiscal Year 2014.
Adamas Pharmaceuticals, Inc. Key Developments
Adamas Pharmaceuticals, Inc. Announces Additional Findings from Phase 2/3 Study Evaluating ADS-5102 for the Treatment of Levodopa-Induced Dyskinesia
Jun 15 15
Adamas Pharmaceuticals, Inc. announced additional findings from its Phase 2/3 study (EASED) evaluating ADS-5102 for the treatment of levodopa-induced dyskinesia (LID), a movement disorder associated with the treatment of Parkinson's disease. Patient diary data were analyzed to characterize the time course of troublesome LID and other Parkinson's disease states during waking hours, synchronized to the patients' wake-up times as well as to elucidate the impact of treatment with ADS-5102. These data showed that troublesome LID was reported throughout the day. After eight weeks of treatment, the majority of ADS-5102-treated patients reported an increase in the quality of ON time by increasing ON time without troublesome LID throughout the morning, afternoon and evening. In contrast, placebo-treated patients reported little change in their dyskinesia. After eight weeks of treatment, the majority of ADS-5102-treated patients reported an increase in the quality of ON time by increasing ON time without troublesome LID throughout the morning, afternoon and evening. ON time is the period when the effects of levodopa provide relief from symptoms of Parkinson's disease. In this post hoc analysis, to better understand motor complications experienced throughout waking hours, a data set was assembled synchronized according to each patient's wake-up time. This analysis included data from patient diaries (n= 62) at baseline and after eight weeks of treatment with either ADS-5102 (n=42, all doses) or placebo (n=20). This analysis revealed that prior to treatment (baseline), study participants experienced, over the course of the day, a complex and dynamic pattern of Parkinson's disease states, including ON time with and without troublesome LID and OFF time. After eight weeks of placebo treatment, there was little change in this pattern. In contrast, the majority of ADS-5102-treated individuals were able to maintain ON time without troublesome LID throughout the waking day, for at least 14 hours after waking up. ADS-5102 was generally well tolerated and reported adverse event terms were consistent with Parkinson's disease and the known amantadine safety profile.
Adamas Begins Phase 2 Clinical Trial Assessing ADS-5102 for Treating Multiple Sclerosis Symptoms in Patients with Walking Impairment
Jun 11 15
Adamas Pharmaceuticals, Inc. announced the initiation of a Phase 2 clinical trial with ADS-5102 (amantadine HCl) in individuals with multiple sclerosis (MS) who have walking impairment. The company to initiate this Phase 2 trial in MS patients with walking impairment to further its understanding of the safety and tolerability of ADS-5102 and to obtain data to guide its development efforts. As its Phase 3 trials of ADS-5102 in levodopa-induced dyskinesia continue to move forward, the company is identifying additional indications that will allow to leverage its wholly-owned, extended-release formulation of amantadine and bring new treatment options to individuals in need. This Phase 2 study is a multi-center, randomized, double-blind, placebo-controlled, two arm, parallel group study of ADS-5102 in 60 individuals with MS who have walking impairment. All participants will be on a stable regimen of MS medications for at least 30 days prior to screening and will continue the same dose and regimen for the duration of their study participation. The primary study objective is to evaluate the safety and tolerability of ADS-5102 dosed at 340 mg once daily at bedtime in an MS population. Efficacy measurements will include assessments of walking and fatigue. The treatment duration will be four weeks with top-line results anticipated in 2016.
Adamas Pharmaceuticals Seeks Acquisitions
May 19 15
Adamas Pharmaceuticals, Inc. (NasdaqGM:ADMS) is looking for acquisition opportunities. Adamas Pharmaceuticals has filed a shelf registration in the amount of $150 million and except as described in any applicable prospectus supplement or in any free writing prospectuses we have authorized for use in connection with a specific offering, we currently intend to use the net proceeds from the sale of the shares of our common stock offered by us hereunder, if any, for working capital, capital expenditures and other general corporate purposes, which may include costs of funding future acquisitions or for any other purpose we describe in the applicable prospectus supplement
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|